Indivior Plc (INDV)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Indivior Plc Stock (INDV) Company Profile

Indivior Plc

Healthcare (1174)

804-379-1090

234 BATH ROAD, SLOUGH, BERKSHIRE

최신 SEC 제출 서류

INDV's Discussions on Twitter

INDV을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
INDV Indivior Plc	13.95	1.71B	1.12B	5.00M	-383.00M	0.01
RGC Regencell Bioscience Holdings Ltd	17.40	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	156.17	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.38	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.10	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.76	20.17B	16.54B	-1.64B	749.00M	-1.45

Indivior Plc Stock (INDV) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-01-28	개시	Rodman & Renshaw	Buy
2024-07-23	개시	Piper Sandler	Overweight
2024-04-03	개시	Craig Hallum	Buy
2023-07-13	개시	Northland Capital	Outperform

Indivior Plc 주식(INDV)의 최신 뉴스

Indivior Plc (INDV) 재무 분석

Indivior Plc (INDV)

Indivior Plc Stock (INDV) Company Profile

INDV을(를) 다른 주식과 비교

Indivior Plc Stock (INDV) Upgrades & Downgrades

Indivior Plc 주식(INDV)의 최신 뉴스

Indivior PLC Announces Changes in Major Holdings - TipRanks

Wirral Council v Indivior/Reckitt: Supreme Court refuses permission to appeal representative action strike out - stewartslaw.com

Indivior PLC Corrects Director Shareholding Disclosure - TipRanks

REGIndivior PLCDirector/PDMR ShareholdingCorrection - TradingView

Naloxone Market to Reflect Significant Incremental - openPR.com

Indivior Directors Increase Stake in Company Shares - TipRanks

Suboxone Market Set to Witness Growth as Opioid Dependency - openPR.com

Substance Abuse Treatment Market Size, Trends & Growth - openPR.com

Indivior PLC Announces Changes in Major Shareholdings - MSN

Indivior-Funded Study Suggests Opvee Outperforms Narcan. But at What? - Filter

INDV DEADLINE ALERT: Bernstein Liebhard LLP Reminds Indivior PLC Investors of Upcoming Deadline - ACCESS Newswire

Indivior PLC (INDV) Stock Analysis: Exploring a 9.21% Potential Upside Amidst Strategic Developments - DirectorsTalk Interviews

Suboxone Market Is Booming Nationwide with New Formulations - openPR.com

Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire

Indivior PLC Announces Change in Major Shareholder Holdings - TipRanks

Levi & Korsinsky Notifies Shareholders of Indivior PLC(INDV) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - GlobeNewswire Inc.

Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN

Indivior PLC (INDV) Stock Analysis: Evaluating the 17.71% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm - ACCESS Newswire

Indivior’s exit comes as no surprise - The Times

Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming DeadlineINDV - ACCESS Newswire

Indivior PLC (INDV) Stock Price Down 3.27% on Jun 2 - GuruFocus

Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com

Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo

Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media

Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd

Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine

Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media

Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media

FTSE pharma giant joins London stock market exodus - The Telegraph

Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus

Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news

Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria

Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq

Indivior to cancel secondary listing in London - Sharecast.com

Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg.com

Drug maker Indivior to abandon London stock market for the US - Yahoo

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - GuruFocus

kalkine: FTSE 350 firm Indivior PLC (LON:INDV) to leave London listing after Nasdaq shift - Kalkine Media

Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks

Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo

Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com

Indivior Announces Intention to Cancel Secondary Listing on Lond - GuruFocus

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire

Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve

Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa

Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus

Indivior appoints Patrick Barry as Chief Commercial Officer - Investing.com India

Indivior Plc (INDV) 재무 분석

매출

순이익

현금흐름

주당 순 이익

INDV과 유사한 종목